Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547049 | 0.85 | — | — | |
| SCHEMBL16837824 | 0.82 | CYP3A4 (0.39) | CYP3A4CYP2C9PKMCYP2C19RECQL | |
| SCHEMBL1971946 | 0.81 | NPSR1 (0.42) | CYP3A4NPSR1LMNAALDH1A1 | |
| SCHEMBL4864227 | 0.81 | NPSR1 (0.47) | CYP3A4NPSR1LMNAALDH1A1 | |
| SCHEMBL2305290 | 0.79 | NPSR1 (0.45) | CYP3A4NPSR1LMNAALDH1A1 | |
| SCHEMBL4872719 | 0.79 | NPSR1 (0.45) | CYP3A4NPSR1LMNAALDH1A1 | |
| SCHEMBL4866927 | 0.78 | NPSR1 (0.35) | CYP3A4NPSR1LMNA | |
| SCHEMBL31711898 | 0.76 | NPSR1 (0.34) | NPSR1LMNA | |
| SCHEMBL4863377 | 0.74 | NPSR1 (0.33) | NPSR1LMNA | |
| SCHEMBL4863381 | 0.74 | NPSR1 (0.33) | NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102383-A1 | LPAR1 Inhibitors | ABBVIE INC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2025226510-A1 | LPAR1 INHIBITORS | ABBVIE INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640274-A1 | LPAR1 INHIBITORS | AbbVie Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3092229-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| WO-2015103509-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| US-8816090-B2 | Benzisoxazole derivatives | PFIZER INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1856114-B1 | BENZISOXAZOLE DERIVATIVES | PFIZER (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| US-20080207690-A1 | Benzisoxazole Derivatives | RAQUALIA PHARMA INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1856114-A1 | BENZISOXAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090224-A1 | BENZISOXAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102383-A1 | LPAR1 Inhibitors | LPAR1, LPAR6, LPAR2 | CYP3A4 4385/4885CYP2C9 3881/4885PKM 3802/4885 |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | DGAT1, DGAT2, SOAT1 | CYP3A4 2220/4885CYP2C9 2703/4885PKM 2576/4885 |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | CYP3A4 387/4885CYP2C9 450/4885PKM 1483/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | CYP3A4 544/4885CYP2C9 479/4885PKM 1888/4885 |
| US-20080207690-A1 | Benzisoxazole Derivatives | BRS3, MRGPRX4, HTR4 | CYP3A4 142/4885CYP2C9 273/4885PKM 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.